PBMs Capture 340B Discounts Meant for Safety-Net Patients

The 340B Drug Pricing Program requires drug manufacturers to sell medications to qualifying safety-net hospitals and clinics at steep discounts — typically 25-50% off list price. These providers are supposed to use the savings to fund care for uninsured and underinsured patients. But PBMs have systematically reduced reimbursement rates to 340B providers, effectively capturing the 340B discount for themselves rather than letting it flow to patient care. Here is how the squeeze works: a 340B hospital buys a drug for $20 (340B price). The PBM reimburses the hospital $25 — the same rate it would pay any pharmacy, even though a non-340B pharmacy acquired that drug for $80. The hospital's $5 margin is far less than the $60 discount intended to fund safety-net care. Meanwhile, the PBM pockets the difference by paying less to the 340B provider than it charges the plan sponsor. Some PBMs have gone further, creating discriminatory reimbursement rates specifically for 340B claims that are lower than standard pharmacy reimbursement. This directly harms the most vulnerable patients in the U.S. healthcare system. 340B hospitals serve disproportionately low-income, uninsured, and minority patient populations. When PBMs erode 340B savings, these providers cut free medication programs, reduce clinic hours, or close outpatient pharmacy services entirely. The Health Resources and Services Administration (HRSA) estimates that 340B savings fund services for over 50 million patients annually. Every dollar a PBM extracts from the program is a dollar that does not reach an uninsured patient's prescription or a community health center's operating budget. The exploitation persists because the 340B statute, enacted in 1992, did not anticipate the rise of PBMs and contains no provisions governing PBM conduct toward 340B entities. HRSA has limited enforcement authority over PBMs since they are not parties to the 340B program. Congress has debated 340B reform for years but cannot agree on whether the problem is PBM exploitation, hospital overuse, or both, resulting in legislative paralysis. The structural root cause is a collision between two opaque systems: the 340B program, which lacks transparency requirements for how savings are used, and the PBM reimbursement system, which lacks transparency in how rates are set. PBMs argue they should not subsidize 340B margins; 340B providers argue PBMs are stealing savings meant for patients. Without clear federal rules on reimbursement floors for 340B claims, PBMs will continue ratcheting down payments because they face no penalty for doing so.